

PATENT  
USSN 09/990,080  
Docket 018/258c

CLAIM AMENDMENTS

1. (*Currently amended*) A protein, peptide, or peptide mimetic that inhibits human telomerase, which ~~either: a) has a sequence comprising at least 10 consisting of at least 500 consecutive amino acids in SEQ. ID NO:2, or encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of DNA that hybridizes to a sequence complementary to SEQ. ID NO:1 at 5°C to 25°C below  $T_m$  in aqueous solution at 1 M NaCl,~~

wherein  $T_m$  is the melting temperature of double-stranded DNA having the sequence of SEQ. ID NO:1 under the same reaction conditions;

but which except that said protein, peptide, or peptide mimetic contains one or more deletions consisting, each of which consists essentially of:

- a) residues 560-565,
- b) residues 930-934, or
- c) at least 10 consecutive amino acids from residues 323-450,
- d) at least 10 consecutive amino acids from residues 637-660,
- e) at least 10 consecutive amino acids from residues 748-766,
- f) at least 10 consecutive amino acids from residues 1055-1071, or
- g) at least 10 consecutive amino acids from residues 1084-1116

of SEQ. ID NO:2

~~+ or b) has a sequence consisting essentially of FFVTE (SEQ. ID NO:3); FVVT (SEQ. ID NO:6), or at least 10 consecutive amino acids from YGVLLKTHCPLRAA (SEQ. ID NO:4).~~

BEST AVAILABLE COPY

PATENT  
USSN 09/990,080  
Docket 018/258c

2. *(Currently amended)*

~~The protein, peptide, or peptide mimetic of claim 1, which has a sequence comprising at least 10 consecutive amino acids in SEQ. ID NO:2, or encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of a sequence complementary to SEQ. ID NO:1; but which contains one or more deletions consisting essentially of residues 560-565, residues 930-934, or at least 10 consecutive amino acids from residues 323-450, 637-660, 748-766, 1055-1071, or 1084-1116 of SEQ. ID NO:2~~

A protein, peptide, or peptide mimetic that inhibits human telomerase, which has a sequence consisting of at least 500 consecutive amino acids of SEQ. ID NO:2; except that it contains one or more deletions, each of which consists essentially of :

- a) residues 560-565,
- b) residues 930-934, or
- c) at least 10 consecutive amino acids from residues 323-450,
- d) at least 10 consecutive amino acids from residues 637-660,
- e) at least 10 consecutive amino acids from residues 748-766,
- f) at least 10 consecutive amino acids from residues 1055-1071, or
- g) at least 10 consecutive amino acids from residues 1084-1116

of SEQ. ID NO:2.

3. *(Currently amended)* ~~The protein, peptide, or peptide mimetic of claim 2~~ claim 1, which has a ~~sequence comprising at least 25 consecutive amino acids in SEQ. ID NO:2; but which contains one or more deletions consisting essentially of residues 560-565, 930-934, 323-450, 637-660, 748-766, 1055-1071, or 1084-1116 of SEQ. ID NO:2.~~
4. *(Currently amended)* The protein, peptide, or peptide mimetic of claim 2, which ~~comprises~~ consists essentially of full-length human telomerase amino acid sequence, except for said deletion(s).
5. *(Original)* ~~The protein, peptide, or peptide mimetic of~~ A protein or peptide according to claim 2, which is a dominant negative mutant.
6. *(Currently amended)* The protein, peptide, or peptide mimetic of ~~claim 5~~ claim 2, which binds human telomerase RNA component but lacks processive telomerase activity.
7. *(Currently amended)* The protein, peptide, or peptide mimetic of ~~claim 6~~ claim 2, which binds human telomeres but lacks processive telomerase activity.
8. **CANCELLED**

PATENT  
USSN 09/990,080  
Docket 018/258c

9. *(Currently amended)* ~~The peptide mimetic of claim 8~~ A peptide mimetic according to claim 13, wherein one or more linkages between consecutive amino acids in the mimetic is  $-\text{CH}_2\text{NH}-$ ,  $-\text{CH}_2\text{S}-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$ ,  $-\text{C}(=\text{O})\text{CH}_2-$ ,  $-\text{CH}(\text{OH})\text{CH}_2-$ , or  $-\text{CH}_2\text{SO}-$ .
10. *(Original)* A method of inhibiting telomerase catalytic activity, comprising introducing a protein, peptide, or peptide mimetic according to claim 1 into an environment containing telomerase reverse transcriptase.
11. *(Currently amended)* A method of inhibiting telomerase catalytic activity, comprising introducing a protein, peptide, or peptide mimetic according to claim 13 into an environment containing telomerase reverse transcriptase and telomerase RNA component ~~a means that inhibits binding of the transcriptase to the RNA component.~~
12. *(Original)* A method of inhibiting telomerase catalytic activity in a cell, comprising expressing in the cell a nucleic acid encoding a protein or peptide according to claim 2.
13. *(Currently amended)* A protein, peptide, or peptide mimetic that ~~is a dominant negative mutant of human telomerase reverse transcriptase having~~ has a means for inhibiting telomerase activity.
14. *(Currently amended)* The protein, peptide, or peptide mimetic of claim 13, which ~~comprises~~ has a means for binding telomerase RNA component, but which lacks telomerase catalytic activity.
15. *(Previously presented)* The protein, peptide, or peptide mimetic of claim 13, which lacks a means for binding telomerase RNA component.

PATENT  
USSN 09/990,080  
Docket 018/258c

16. *(Currently amended)* The protein, peptide, or peptide mimetic of claim 14, wherein the telomerase inhibition means ~~comprises at least 10~~ consists of at least 500 consecutive amino acids in SEQ. ID NO:2, or encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of DNA that hybridizes to a sequence complementary to SEQ. ID NO:1 at 5°C to 25°C below  $T_m$  in aqueous solution at 1 M NaCl,  
wherein  $T_m$  is the melting temperature of double-stranded DNA having the sequence of SEQ. ID NO:1 under the same reaction conditions;  
but which except that said protein, peptide, or peptide mimetic contains one or more deletions consisting , each of which consists essentially of :  
a) residues 560-565,  
b) residues 930-934, or  
c) at least 10 consecutive amino acids from residues 323-450,  
d) at least 10 consecutive amino acids from residues 637-660,  
e) at least 10 consecutive amino acids from residues 748-766,  
f) at least 10 consecutive amino acids from residues 1055-1071, or  
g) at least 10 consecutive amino acids from residues 1084-1116  
of SEQ. ID NO:2.
17. *(Currently amended)* The protein, peptide, or peptide mimetic ~~of claim 14, wherein the telomerase inhibition means comprises at least 25 consecutive amino acids in SEQ. ID NO:2, but~~  
of claim 16, wherein the telomerase inhibition means contains one or more deletions consisting essentially of residues 560-565, residues 930-934, or at least 10 consecutive amino acids from residues 323-450, 637-660, 748-766, 1055-1071, or 1084-1116 of SEQ. ID NO:2.
18. *(Withdrawn)* The protein, peptide, or peptide mimetic of claim 15, wherein the telomerase inhibition means has a sequence consisting essentially of FFYVTE (SEQ. ID NO:3).
19. *(Withdrawn)* The protein, peptide, or peptide mimetic of claim 15, wherein the telomerase inhibition means has a sequence consisting essentially of FYVT (SEQ. ID NO:5).
20. *(Withdrawn)* The protein, peptide, or peptide mimetic of claim 15, wherein the telomerase inhibition means has a sequence consisting essentially of at least 10 consecutive amino acids in YGVLLKTHCPLRAA (SEQ. ID NO:4).
21. *(New)* A method of inhibiting telomerase catalytic activity in a cell, comprising expressing in the cell a nucleic acid encoding a protein or peptide according to claim 13.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**